Available Trials

A randomized, multicenter, double blind Phase 3 study of PD-0332991 (Oral CDK 4/6 inhibitor) plus letrozole versus placebo plus letrozole for the treatment of postmenopausal women with ER(+), HER2(-) breast cancer who have not received any prior systemic anti-cancer treatment for advanced disease.

• Bladder
• Breast
• Colon
• Gastrointestinal
• Head and Neck
• Leukemia
• Liver
• Lung
• Lymphoma
• Pancreatic
• Prostate
• Renal
• Solid Tumors

 

Bladder

• Durvalumab Monotherapy for Advanced Bladder Cancer

  An Open-Label, Multi-Centre, Safety Study of Fixed-Dose Durvalumab + Tremelimunab Combination Therapy or Durvalumab Monotherapy in Advanced Solid Malignancies (STRONG)
  

  ---

Breast

• Eribulin Mesylate + Pembrolizumab for Triple Negative Breast Cancer

  An Open-Label, Single-Arm Multicenter Phase 1b/2 Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Subjects With Metastatic Triple-Negative Breast Cancer
  

  ---

• Sacituzumab Govitecan vs. SOC for Triple Negative Breast Cancer

  An International, Multi-Center, Open-Label, Randomized, Phase III Trial of Sacituzumab Govitecan versus Treatment of Physician Choice in Patients with Metastatic Triple-Negative Breast Cancer Who Received at Least Two Prior Treatments
  

  ---

• Post-Mastectomy/Lumpectomy Radiation after Neoadjuvant Chemotherapy

  A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy
  

  ---

Colon

• Standard of Care +/- Nivolumab in 1st Line Metastatic Colorectal Cancer

  An Open-Label Exploratory Phase 2/3 Study of Nivolumab with Standard of Care Therapy vs Standard of Care Therapy for First-Line Treatment of Metastatic Colorectal Cancer
  

  ---

Gastrointestinal

• Nivolumab +/- Ipilimumab with Fluorouracil plus Cisplatin in Esophageal Squamous Cell

  A Randomized Phase 3 Study of Nivolumab plus Ipilimumab or Nivolumab Combined with Fluorouracil plus Cisplatin versus Fluorouracil plus Cisplatin in Subjects with Unresectable Advanced, Recurrent or Metastatic Previously Untreated Esophageal Squamous Cell Carcinoma
  

  ---

Head and Neck

• Atezolizumab in Adjuvant Setting for Advanced Squamous Cell Carcinoma of the Head and Neck

  A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab (anti PD-L1 antibody) as Adjuvant Therapy after definitive local therapy in patients with high risk locally advanced Squamous Cell Carcinoma of the Head and Neck
  

  ---

Leukemia

• Azacitidine +/- Pevonedistat for High Risk MDS, CML, or Low-Blast AML

  A Phase 3, Randomized, Controlled, Open-label, Clinical Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Low-Blast Acute Myelogenous Leukemia
  

  ---

Liver

• BBI608 with Sorafenib or BBI503 with Sorafenib in Hepatocellular Carcinoma

  A Phase Ib/II Clinical Study of BBI608 in Combination with Sorafenib or BBI503 in Combination with Sorafenib in Adult Patients with Hepatocellular Carcinoma
  

  ---

Lung

• Pembrolizumab + Epacadostat alone or with Chemotherapy for 1st Line NSCLC

  A Randomized Phase 3 Study of the Combination of Pembrolizumab (MK-3475) Plus Epacadostat (INCB024360) Alone or with Platinum-based Chemotherapy Versus Pembrolizumab Plus Platinum-based Chemotherapy Plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer
  

  ---

Lymphoma

• Polatuzumab Vedotin with R-CHP versus R-CHOP in DLBCL

  A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial comparing the efficacy and safety of Polatuzumab Vedotin in combination with Rituximab and CHP (R-CHP) and CHOP (R-CHOP) in previously untreated patients with Diffuse Large B-Cell Lymphoma
  

  ---

• ABP798 versus Rituximab in Non-Hodgkin Lymphoma

  A Randomized, Double-blind study evaluating the efficacy, safety and immunogenicity of ABP 798 compared with Rituximab in subjects with CD20 postiive B-Cell Non-Hodgkin Lymphoma (NHL)
  

  ---

• Brentuximab Vedotin in combination with Nivolumab for Hodgkins Lymphoma

  A phase 2 open-label study of Brentuximab Vedotin in combination with Nivolumab in front-line therapy of Hodgkin Lymphoma (HL) in adults age 60 and above
  

  ---

• Rituximab +/- Ibrutinib for Follicular Lymphoma

  A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Rituximab versus Placebo in Combination with Rituximab in Treatment Naïve Subjects with Follicular Lymphoma
  

  ---

• TGR-1202 in patients with DLBCL, FL, SLL, or MZL

  A phase 2b randomized study to assess the efficacy and safety of the combination of Ublituximab + TGR-1202 and TGR-1202 alone in patients with previously treated Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Small Lymphocytic Lymphoma, or Marginal Zone Lymphoma
  

  ---

• Lenalidomide/Rituxan for FL, MZ, ML

  A phase 3b randomized study of Lenalidomide (CC-5013) plus Rituximab maintenance therapy followed by Lenalidomide single-agent maintenance versus Rituximab maintenance in subjects with relapsed/refractory Follicular, Marginal Zone or Mantle Cell Lymphoma
  

  ---

Pancreatic

• BBI-608 with nab-Paclitaxel and Gemcitabine in Pancreatic Adenocarcinoma

  A Phase III Study of BBI-608 plus nab-Paclitaxel with Gemcitabine in Adult Patients with Metastatic Pancreatic Adenocarcinoma.
  

  ---

Prostate

• Androgen Deprivation Therapy and High Dose Radiotherapy +/- Whole-Pelvic Radiotherapy

  Androgen Deprivation Therapy and High Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial
  

  ---

Renal

• Pembrolizumab + Epacadostat versus Sunitinib or Pazopanib for 1st line Renal Cell

  A Randomized, Open-Label, Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab (MK-3475) plus Epacadostat vs Standard of Care (Sunitinib or Pazopanib) as First-Line Treatment for Locally Advanced or Metastatic Renal Cell Carcinoma (mRCC)
  

  ---

Solid Tumors

• MGCD516 for Solid Tumor Malignancies

  A Phase 1/1b Study of MGCD516 in Patients With Advanced Solid Tumor Malignancies
  

  ---

• Nivolumab in Advanced or Metastatic Malignancies

  An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies
  

  ---